Hosted on MSN1d
RNA Stock Hits Record High on Entering the Cardiac Disease Space
This upside in RNA stock is being driven by the encouraging clinical development of its three rare neuromuscular programs — ...
EurekAlert!18d
Unexpected findings provide a deeper understanding of Myotonic Dystrophy Type 1
People with Myotonic Dystrophy Type 1 (DM1), the most common adult-onset form of muscular dystrophy, progressively lose muscle mass and strength in their lower legs, hands, neck and face. The effects ...
Avidity Biosciences jumps 16%; reaches all-time high
Avidity Biosciences (NASDAQ:RNA) has surged ~16% Wednesday, reaching an all-time high of $56.00 earlier in the trading ...
Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases
Investors consider Dyne Therapeutics' treatments for muscle diseases and strong cash position as a speculative Buy ...
Medical Xpress23d
Mouse model reveals liver involvement in muscular dystrophy
A new mouse model mimicking the liver symptoms of myotonic dystrophy type 1—the most prevalent form of adult-onset muscular dystrophy—provides insight into why patients develop fatty liver ...
Dyne Therapeutics Receives Buy Rating Following IND Clearance and Promising Trial Updates
Analyst Michael Ulz from Morgan Stanley reiterated a Buy rating on Dyne Therapeutics (DYN – Research Report) and keeping the price target ...
onmanorama7d
Actor Nepoleon's son's wedding: What is muscular dystrophy?
According to the Mayo Clinic, muscular dystrophy is a group of diseases that cause loss of muscle mass and progressive ...
Dyne Therapeutics Reveals Q3 Results and Trial Updates
Dyne Therapeutics, Inc. ( (DYN) ) has released its Q3 earnings. Here is a breakdown of the information Dyne Therapeutics, Inc. presented to its ...